Day: September 25, 2024

MELVILLE, N.Y., Sept. 25, 2024 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), a provider of diverse business continuity solutions for disaster-recovery, cloud infrastructure, cyber-security, and IT automation, today announced that its subsidiary, CloudFirst, has secured an expanded agreement through its infrastructure partner, servicing a billion-dollar insurance company. The client is currently utilizing the Company’s security services for their IBMi system and has now opted to enhance their disaster recovery capabilities by moving to a fully managed hosted target system. Through this agreement, Data Storage Corporation will provide a fully managed hosting solution that includes cloud backup, backup management, and replication management ensuring seamless and reliable data continuity. Hal...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK’s largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing. “We are thrilled to partner with Intelligent Fingerprinting to enhance our approach to workplace safety,” said Emma Bullock, Head of People at Thanet Earth. “Fingerprint drug testing allows us to ensure that our team is operating in a safe and efficient manner without interrupting our daily operations.” Thanet Earth is a leader in the UK’s horticultural sector, producing millions of tomatoes, cucumbers, and peppers annually for major retailers nationwide. The company...

ANDOVER, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) — Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, will hold a conference call on Wednesday, October 9, 2024 at 9:00 a.m. Eastern time to discuss its financial results for the fiscal third quarter ended August 31, 2024. Financial results will be issued in a press release prior to the call. Byrna management will host the presentation, followed by a question-and-answer period. Date: Wednesday, October 9, 2024Time: 9:00 a.m. Eastern timeToll-Free Dial-In: 877-709-8150International Dial-In: +1 201-689-8354Conference ID: 13748618 Please call the conference telephone number 10 minutes prior to the start time. An operator will...

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-8 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Monday, September 30, 2024. The reverse stock split is intended to increase the per share trading price of Sonnet’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market (Rule 5550(a)(2)). Sonnet’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “SONN” and under a new CUSIP number, 83548R402. As a result of the reverse stock split, every eight...

Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCathRenovoCath ImageRenovoCath ImageLOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a local drug-delivery platform, today announced that it is increasing the production of its FDA-cleared RenovoCath catheter-based delivery system due to increased demand for targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists. RenovoRx has signed a new project work order with its principal manufacturing partner, Medical Murray of North Barrington, IL, providing for an expanded relationship and as RenovoRx...

DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the enrollment of four additional subjects in a 10-day period in its pivotal NEUTRALIZE-AKI trial, bringing total trial enrollment to 46. This trial is evaluating the safety and efficacy of SeaStar Medical’s proprietary therapeutic Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI) in the intensive care unit (ICU) receiving continuous kidney replacement therapy (CKRT). “We are encouraged to see a recent uptick in enrollment following a slow summer period due to low census across many of the ICUs participating in this trial,” said Kevin Chung, MD, Chief Medical Officer...

Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards,Investor RelationsColoplast A/STel. +45 4911 1800   For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@coloplast.com Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@coloplast.com Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@coloplast.com AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917 Websitewww.coloplast.com   This announcement...

On September 25, Merko Ehitus group’s 100% subsidiaries OÜ Merko Ehitus Ventures and AS Merko Ehitus Eesti signed an agreement, according to which 50% of the share in AS Connecto Eesti, so far owned by Merko Ehitus Eesti, will be transferred to OÜ Merko Ehitus Ventures through the division. The balance sheet date of the division shall be 1 January 2025. Merko Ehitus group is harmonizing with the change in Estonia the structure of its subsidiaries, the structure based on business segments is used in all home markets of the group. AS Merko Ehitus Eesti (merko.ee) is a recognised Estonian construction company, which offers construction services in general construction, civil engineering and residential construction. AS Connecto Eesti (connecto.ee) is a leading Estonian construction company that designs, builds and maintains electricity,...

PGCVanessa Tortorice, Peapack Private, Senior Managing DirectorBEDMINSTER, NJ, Sept. 25, 2024 (GLOBE NEWSWIRE) — Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) and Peapack Private, a division of Peapack-Gladstone Bank, are proud to announce that Vanessa Tortorice has joined Peapack Private’s New York City location as Senior Managing Director.  Vanessa joins a team of highly-skilled commercial bankers at Peapack Private, where she will contribute to the growth of commercial and industrial business in the New York market. She is dedicated to providing tailored banking solutions to help clients achieve their long-term financial goals. With a proven track record in financial services, Vanessa brings 12 years of experience to Peapack Private.  Previously, she served as Vice President and Senior Business...

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases – – Oral presentation taking place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST – SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at the American College of Rheumatology’s annual meeting, ACR Convergence 2024, being held from November 14 to 19, 2024 in Washington, DC. Kronos Bio is exploring...